Miso Kim

785 total citations
30 papers, 463 citations indexed

About

Miso Kim is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Miso Kim has authored 30 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Miso Kim's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). Miso Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). Miso Kim collaborates with scholars based in South Korea, United States and Puerto Rico. Miso Kim's co-authors include Tae Min Kim, Dae Seog Heo, Bhumsuk Keam, Dong‐Wan Kim, Soyeon Kim, Dong‐Wan Kim, Yoon Kyung Jeon, Hyoung Chul Choi, Jae Hyang Lim and Soyeon Kim and has published in prestigious journals such as Journal of Biological Chemistry, Scientific Reports and Life Sciences.

In The Last Decade

Miso Kim

28 papers receiving 461 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miso Kim South Korea 12 245 181 156 127 91 30 463
Jii Bum Lee South Korea 12 322 1.3× 187 1.0× 140 0.9× 171 1.3× 61 0.7× 47 545
Céline Clémenson France 15 299 1.2× 238 1.3× 93 0.6× 186 1.5× 89 1.0× 24 613
Surein Arulananda Australia 9 228 0.9× 230 1.3× 205 1.3× 50 0.4× 83 0.9× 28 469
Sofia Genta Canada 12 434 1.8× 289 1.6× 139 0.9× 170 1.3× 135 1.5× 36 742
Elaine McWhirter Canada 13 300 1.2× 204 1.1× 81 0.5× 72 0.6× 83 0.9× 39 486
Ignacio Wistuba United States 9 195 0.8× 183 1.0× 147 0.9× 60 0.5× 72 0.8× 20 424
Andrew Elliott United States 10 260 1.1× 191 1.1× 146 0.9× 54 0.4× 89 1.0× 99 483
Andrew Cannon United States 10 245 1.0× 252 1.4× 50 0.3× 131 1.0× 79 0.9× 24 501
Tianxiao Xu China 14 255 1.0× 294 1.6× 68 0.4× 107 0.8× 110 1.2× 29 506
Emily K. Slotkin United States 13 213 0.9× 230 1.3× 271 1.7× 57 0.4× 135 1.5× 38 548

Countries citing papers authored by Miso Kim

Since Specialization
Citations

This map shows the geographic impact of Miso Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miso Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miso Kim more than expected).

Fields of papers citing papers by Miso Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miso Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miso Kim. The network helps show where Miso Kim may publish in the future.

Co-authorship network of co-authors of Miso Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Miso Kim. A scholar is included among the top collaborators of Miso Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miso Kim. Miso Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kim, Soo-Min, Jaemoon Koh, Tae Min Kim, et al.. (2025). Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. iScience. 28(2). 111736–111736. 3 indexed citations
3.
Kim, Miso, et al.. (2024). ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion. Cancer Research and Treatment. 57(3). 899–904. 1 indexed citations
4.
Kim, Miso, et al.. (2024). Gene therapy in pediatrics – Clinical studies and approved drugs (as of 2023). Life Sciences. 348. 122685–122685. 4 indexed citations
5.
Kim, Chang Gon, Miso Kim, Seung Tae Kim, et al.. (2022). First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600–mutant advanced melanoma. Journal of the American Academy of Dermatology. 87(5). 989–996. 3 indexed citations
6.
Kim, Seong‐Eun, Bhumsuk Keam, Hyewon Chung, et al.. (2022). Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis. Scientific Reports. 12(1). 12546–12546. 11 indexed citations
7.
Jung, Minsun, Kyung‐Chul Moon, Tae Min Kim, et al.. (2022). ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights. Archives of Pathology & Laboratory Medicine. 146(12). 1460–1470. 4 indexed citations
8.
Kim, Jung Sun, So-Yeon Kim, Jaemoon Koh, et al.. (2022). Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance. Journal of Cancer Research and Clinical Oncology. 149(6). 2355–2365. 7 indexed citations
9.
Kim, Jong-Hwan, Hyun Jung Lim, Jeong‐Hwan Kim, et al.. (2022). DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy. Experimental & Molecular Medicine. 54(8). 1236–1249. 11 indexed citations
10.
Park, Ji‐Eun, Seong‐Eun Kim, Bhumsuk Keam, et al.. (2020). Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. Journal for ImmunoTherapy of Cancer. 8(2). e000873–e000873. 72 indexed citations
11.
Kim, Miso, et al.. (2020). Colorimetric Determination of Singlet Oxygen Scavengers Using a Protein Photosensitizer. BioChip Journal. 14(2). 148–157. 10 indexed citations
12.
Byeon, Seonggyu, Myoung Joo Kang, Yoon Ji Choi, et al.. (2020). Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Translational Cancer Research. 9(5). 3222–3230. 2 indexed citations
13.
Im, Sun-Wha, Jeesoo Chae, Se Song Jang, et al.. (2020). A newly developed capture-based sequencing panel for genomic assay of lung cancer. Genes & Genomics. 42(7). 751–759. 5 indexed citations
14.
Park, Changhee, Jeong Mo Bae, Kwangsoo Kim, et al.. (2020). Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. Cancer Immunology Immunotherapy. 70(6). 1605–1617. 5 indexed citations
15.
Keam, Bhumsuk, Chan-Young Ock, Miso Kim, et al.. (2019). Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. Clinical Lung Cancer. 20(4). e442–e451. 16 indexed citations
16.
Kim, Sehui, Ji-Young Jang, Jaemoon Koh, et al.. (2019). Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. Journal of Experimental & Clinical Cancer Research. 38(1). 462–462. 50 indexed citations
17.
Yoo, Shin Hye, Tae‐Yong Kim, Miso Kim, et al.. (2019). Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer. Clinical Breast Cancer. 20(2). 98–107.e1. 19 indexed citations
18.
Kim, Tae Min, Dong‐Wan Kim, Soyeon Kim, et al.. (2019). Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology. 14(9). 1556–1566. 29 indexed citations
19.
Kim, Ryul, Bhumsuk Keam, Dohee Kwon, et al.. (2016). Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. World Journal of Gastroenterology. 22(37). 8389–8389. 23 indexed citations
20.
Kim, Miso, et al.. (2012). Laminar Flow Activation of ERK5 Protein in Vascular Endothelium Leads to Atheroprotective Effect via NF-E2-related Factor 2 (Nrf2) Activation. Journal of Biological Chemistry. 287(48). 40722–40731. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jii Bum Lee Breakdown of academic impact, for papers by Céline Clémenson Breakdown of academic impact, for papers by Surein Arulananda Breakdown of academic impact, for papers by Sofia Genta Breakdown of academic impact, for papers by Elaine McWhirter Breakdown of academic impact, for papers by Ignacio Wistuba Breakdown of academic impact, for papers by Andrew Elliott Breakdown of academic impact, for papers by Andrew Cannon Breakdown of academic impact, for papers by Tianxiao Xu Breakdown of academic impact, for papers by Emily K. Slotkin
Rankless by CCL
2026